Australia · Delayed Price · Currency is AUD Nufarm Earnings Call Transcripts
Fiscal Year 2026
-
Management highlighted strong H1 FY 2026 results, driven by a shift to higher-margin products, improved cash flow, and disciplined capital allocation. Strategic priorities include cost savings, portfolio rationalization, and growth in hybrid seeds and emerging platforms, with a focus on sustaining positive free cash flow and margin expansion.
-
First half saw 18% EBITDA and 35% NPAT growth year-over-year, with improved margins and cash flow, reduced leverage, and strong segment performance in Europe and Hybrid Seeds. Full-year outlook reaffirmed for strong EBITDA growth, lower leverage, and positive free cash flow.
-
The meeting reviewed a disappointing FY 2025 statutory loss, but highlighted strong underlying crop protection performance and strategic repositioning of the seeds business. No dividend was declared, and a new CEO was introduced. All resolutions received strong shareholder support.
Fiscal Year 2025
-
Revenue grew 3% year-on-year with strong Crop Protection performance and improved margins, but a statutory loss of AUD 165 million was recorded due to non-cash items from Seed Technologies. FY2026 outlook is for EBITDA growth, lower leverage, and positive free cash flow.
-
First half 2025 saw revenue growth and strong crop protection recovery, but Omega-3 price collapse led to a significant write-down and margin pressure. Leverage increased to 4.5x EBITDA, prompting a focus on deleveraging, cost savings, and a review of Seed Technologies' capital structure.
-
The AGM highlighted a challenging FY24 with lower earnings due to industry pressures, but showcased progress in innovation, cost savings, and working capital efficiency. Shareholders expressed concerns about share price, dividends, and governance, with the board emphasizing alignment of incentives and strategic growth initiatives.
Fiscal Year 2024
-
FY24 saw lower earnings and revenue amid industry headwinds, but strong cost and working capital management led to a 25% reduction in net debt. New product launches and growth in Omega-3 and biofuels platforms support a more positive outlook for FY25, with targeted cost savings and inventory reductions.